Table 6 Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival for patients treated by breast conservation

From: High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies

   

Univariate analysis

Multivariate analysis a

 

N

10-year LRRFS (%)(IC 95%)

P b

RR (IC 95%)

P c

RR (IC 95%)

Age (continuous variable)

  

0.0009

0.96 (0.94–0.98)

  

Age (dummy variable) d

<10−6

 

<10−5

 

 >40

382

77 (72–82)

 

1

 

1

 ⩽40

94

49 (38–63)

 

2.6 (1.8–3.7)

 

2.6 (1.7–3.7)

Menopause d

0.1

   

 No

353

69 (63–74)

 

1

  

 Yes

123

80 (73–88)

 

0.7 (0.4–1.1)

  

Clinical tumour stage d

0.81

   

 cT2

391

72 (67–77)

 

1

  

 cT3

85

71 (60–83)

 

1.1 (0.7–1.7)

  

Clinical nodal status d

0.06

   

 cN0

315

73 (68–79)

 

1

  

 cN1

161

68 (60–77)

 

1.4 (1.0–2.1)

  

Histological type d

0.12

   

 Ductal

434

72 (68–77)

 

1

  

 Lobular

42

62 (47–82)

 

1.5 (0.9–2.6)

  

Hormonal receptors d

0.54

   

 HR+

291

72 (66–78)

 

1

  

 HR−

114

68 (59–79)

 

1.1 (0.7–1.7)

  

Histological grade

0.97

   

 Grade 1

71

73 (63–85)

 

1

  

 Grade 2

215

70 (63–77)

 

1.0 (0.6–1.6)

  

 Grade 3

156

72 (64–81)

 

0.9 (0.5–1.6)

  

Mitotic index

0.72

   

 Grade 1

110

71 (62–83)

 

1

  

 Grade 2

125

72 (64–82)

 

1.1 (0.7–1.8)

  

 Grade 3

195

70 (63–78)

 

1.2 (0.8–1.9)

  

Clinical response

0.29

   

 ⩾50%

343

74 (69–79)

 

1

  

 <50%

127

67 (58–77)

 

1.2 (0.8–1.8)

  

Locoregional treatment

<10−3

   

 Postop

308

77 (71–83)

    

 Preop/excl

168

61 (53–70)

 

2.0 (1.4–2.8)

  
  1. HR=hormonal receptor; LRRFS=locoregional recurrence-free survival
  2. aMultivariate analysis after stratification on local treatment.
  3. bLog-rank test.
  4. cLikelihood ratio test.
  5. dFactors entered in the multivariate analysis.
  6. Preop/excl: locoregional treatment consisted in preoperative or exclusive radiotherapy.